How And Where Tougher Clinical Evaluation Measures Under EU MDR Cause Challenges
Executive Summary
A first of its kind study examines how large compared with medium companies are coping with the EU’s strict clinical evidence requirements. The results show how it is the more stringent demands for high-risk devices that are leading to device removals as well as market launch outside the EU.
You may also be interested in...
Optimizing EU Medtech Regulatory Governance And Innovation: First Workshop Shapes Future Study
Work related to the European Commission’s promise to assess the impact of the Medical Device Regulation, including its impact on innovation, is starting to take shape.
Exciting New Opportunities Launched In UK For Innovative Products As IDAP Gets Underway
Medtech developers have just over a month to apply for the pilot phase of a program offering regulatory and practical support to accelerate innovative product access to the UK NHS.
Entire EU Medtech Industry Throws Weight Behind Argument To Structurally Reform MDR And IVDR
The European Commission has conceded to the medtech industry’s calls to delay and modify the new EU regulatory requirements multiple times over the last few years. But will it yield to fresh calls for radical changes being sought by the most powerful lobby yet?